| Autor: |
Thomas Danne, Jochen Seufert, Christian Wagner, Kerstin König, Dirk Raddatz, Rosmarie Weber-Lauffer, Diether Erath, Jost Hilgenberg, Carsten Spies, Maximilian Gabler, Johannes Foersch, Ludwin Ley |
| Jazyk: |
angličtina |
| Rok vydání: |
2020 |
| Předmět: |
|
| Zdroj: |
BMJ Open Diabetes Research & Care, Vol 8, Iss 1 (2020) |
| Druh dokumentu: |
article |
| ISSN: |
2052-4897 |
| DOI: |
10.1136/bmjdrc-2020-001486 |
| Popis: |
Introduction Empagliflozin reduced morbidity and mortality in patients with type 2 diabetes mellitus (T2DM) in clinical trials. A registry study was undertaken to describe evolution of patient characteristics and assess the real-world effectiveness/safety of empagliflozin.Research design and methods Data from the Diabetes Patienten Verlaufsdokumentation (DPV)/Diabetes Versorgungsevaluation (DIVE) registries on 9571 adults with T2DM (registered in 2014–2019) receiving empagliflozin were used. Patients were grouped according to the following: early users (group 1; n=505) received empagliflozin before the EMPA-REG OUTCOME study publication (mid-September 2015); intermediate users (group 2; n=2961) started empagliflozin after the EMPA-REG OUTCOME publication but before the European Medicines Agency label change (from mid-September 2015 to mid-January 2017); and late users (group 3; n=6105) started empagliflozin after mid-January 2017. Data on clinical and treatment characteristics were collected.Results Over time, the proportion of recipients aged |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
